| Cover | 1 |
---|
| Contents | 6 |
---|
| Preface | 8 |
---|
| Non-Alcoholic Fatty Liver Disease | 10 |
---|
| Abstract | 10 |
| Nomenclature | 10 |
| Epidemiology and Natural History | 11 |
| Pathogenesis | 13 |
| Clinical Features and Investigation | 15 |
| Therapy | 16 |
| Conclusions | 21 |
| References | 21 |
| Fibrosis in the GI Tract: Pathophysiology, Diagnosis and Treatment Options | 24 |
---|
| Abstract | 24 |
| Cellular and Molecular Mechanisms of Fibrosis in the GI Tract | 24 |
| Liver Fibrosis | 32 |
| Pancreatic Fibrosis | 33 |
| Intestinal Fibrosis | 34 |
| Clinical Evaluation of Fibrosis Progression/Regression | 34 |
| Potential Anti-Fibrogenic Strategies | 35 |
| References | 36 |
| Chronic Hepatitis B: Pathophysiology, Diagnosis and Treatment Options | 41 |
---|
| Abstract | 41 |
| Phases of Hepatitis B Infection | 43 |
| Role of Viral Load | 43 |
| Immunopathogenesis | 44 |
| Treatment Options in Chronic Hepatitis B | 46 |
| Summary | 48 |
| References | 49 |
| Chronic Hepatitis C: Pathophysiology, Diagnosis and Treatment Options | 51 |
---|
| Abstract | 51 |
| Viral Cycle | 51 |
| Interferon Signalling and HCV Infection | 54 |
| Innate and Adaptive Immunity to HCV Infection | 56 |
| Progression of Fibrosis in Hepatitis C | 58 |
| Predictive Factors of Response to Treatment | 59 |
| Genome-Wide Association Studies Identified SNPs in the IL28B Region Associated with Response to Treatment | 60 |
| Molecular Signatures of Response in Liver | 60 |
| Standard of Care: Combined PEG-IFN Plus Ribavirin | 62 |
| Specifically Targeted Antiviral Therapy for HCV | 62 |
| Conclusion | 64 |
| Acknowledgment | 64 |
| References | 65 |
| Clinical Update on Inflammatory Disorders of the GI Tract: Liver Transplantation | 68 |
---|
| Abstract | 68 |
| Primary Sclerosing Cholangitis | 69 |
| Autoimmune Hepatitis | 74 |
| PSC and AIH: Similarities and Differences | 76 |
| References | 78 |
| Hepatocellular Carcinoma | 81 |
---|
| Abstract | 81 |
| Incidence and Epidemiology | 81 |
| Screening and Surveillance | 82 |
| Diagnosis and Staging | 82 |
| Treatment | 83 |
| Surgical Interventions for Advanced HCC | 84 |
| Locoablative Therapies with Curative Intent | 86 |
| Established palliative Therapeutic Intervention for Advanced HCC | 87 |
| Transarterial Chemoembolization | 87 |
| Drug Treatment for Advanced HCC | 88 |
| Non-Established and Experimental Treatment Options | 89 |
| References | 89 |
| Coeliac Disease | 92 |
---|
| Abstract | 92 |
| Coeliac Disease, Epidemiology and Symptoms | 92 |
| Pathogenesis of Coeliac Disease | 94 |
| Genetic and Other Risk Factors | 98 |
| Oral Tolerance to Gluten | 98 |
| Intestinal Gluten Transport | 98 |
| Novel Therapies for Coeliac Disease | 99 |
| Conclusions | 99 |
| Acknowledgments | 101 |
| References | 101 |
| Anti-TNF Therapy in Inflammatory BowelDiseases | 104 |
---|
| Abstract | 104 |
| Methods | 105 |
| Results | 105 |
| Conclusion | 113 |
| References | 114 |
| Role of Epithelial Cells in Inflammatory Bowel Disease | 117 |
---|
| Abstract | 117 |
| Endoplasmic Reticulum Stress | 118 |
| Autophagy | 120 |
| NOD2 | 121 |
| Organic Cation Transporters | 122 |
| NF?B | 123 |
| Conclusion | 124 |
| References | 124 |
| GI Immune Response in Functional GI Disorders | 127 |
---|
| Abstract | 127 |
| Introduction | 127 |
| Presence of Inflammation | 128 |
| Summary | 132 |
| References | 132 |
| Probiotics in GI Diseases | 135 |
---|
| Abstract | 135 |
| Probiotics | 135 |
| Inflammatory Bowel Disease | 136 |
| H. pylori Infection | 139 |
| Irritable Bowel Syndrome | 140 |
| Diverticular Disease | 141 |
| Conclusions | 141 |
| References | 142 |
| Microscopic Colitis | 144 |
---|
| Abstract | 144 |